Valuation: Devyser Diagnostics AB

Market Cap 904M 90.41M 80.31M 75.23M 68.15M 129M 8.71B 130M 351M 4.45B 339M 332M 14.41B P/E 2026 *
88.3x
P/E 2027 * 27.7x
Enterprise Value 857M 85.71M 76.13M 71.31M 64.61M 122M 8.26B 123M 333M 4.22B 322M 315M 13.66B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 2.91x
Free-Float
70.78%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
1 week+7.05%
Current month+8.14%
1 month-10.56%
3 months-35.86%
6 months-32.32%
Current year-53.18%
1 week 4.42
Extreme 4.415
4.82
1 month 4.38
Extreme 4.385
5.36
Current year 4.38
Extreme 4.385
10.56
1 year 4.38
Extreme 4.385
12.72
3 years 4.38
Extreme 4.385
14.2
5 years 4.38
Extreme 4.385
14.2
10 years 4.38
Extreme 4.385
14.2
Manager TitleAgeSince
Chief Executive Officer 59 2025-08-03
Director of Finance/CFO 43 2020-12-31
Chief Tech/Sci/R&D Officer 48 2024-01-31
Director TitleAgeSince
Chairman 57 2021-05-26
Director/Board Member 49 2020-12-31
Director/Board Member 72 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%+7.05% - - 90.82M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-3.38%-9.25%-12.85% 24.53B
Average +0.80%-0.20%+52.55%+125.61% 43.73B
Weighted average by Cap. +1.10%-0.50%+56.58%+134.21%

Financials

2026 *2027 *
Net sales 246M 24.61M 21.86M 20.48M 18.55M 34.99M 2.37B 35.28M 95.5M 1.21B 92.36M 90.4M 3.92B 298M 29.77M 26.45M 24.77M 22.44M 42.33M 2.87B 42.68M 116M 1.46B 112M 109M 4.75B
Net income 10.07M 1.01M 895K 838K 759K 1.43M 97.05M 1.44M 3.91M 49.56M 3.78M 3.7M 161M 31.97M 3.2M 2.84M 2.66M 2.41M 4.55M 308M 4.59M 12.42M 157M 12.01M 11.75M 510M
Net Debt -47.04M -4.71M -4.18M -3.92M -3.55M -6.69M -454M -6.75M -18.27M -232M -17.67M -17.29M -750M -39M -3.9M -3.47M -3.25M -2.94M -5.55M -376M -5.59M -15.14M -192M -14.65M -14.33M -622M
Projected Income Statement - Annual - Devyser Diagnostics AB
Logo Devyser Diagnostics AB
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
Employees
110
Date Price Change
26-10-06 €4.785 +1.16%
26-10-05 €4.730 -1.15%
26-10-02 €4.785 +6.22%
26-10-01 €4.505 +1.81%
26-09-30 €4.425 -0.23%
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Devyser Diagnostics AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
35.58DKK
Average target price
65.94DKK
Spread / Average Target
+85.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Devyser Diagnostics AB